FDA letter sent to Verrica Pharma notes deficiencies in the NDA for VP 102 to treat molluscum contagiosum.
Verrica Pharmaceuticals Inc. announced that the Company received a letter from the FDA as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for… read more.